

First Databank (FDB) Releases New, Expanded Medication Decision Support Solutions at HIMSS13 Conference

FDB solutions support interoperability for Meaningful Use Stages 1 & 2, address alert fatigue and provide support for controlled substances prescribing

South San Francisco, CA – February 28, 2013 – First Databank (FDB), a leading provider of [clinical drug knowledge](http://www.fdbhealth.com/why-fdb/overview/) (<http://www.fdbhealth.com/why-fdb/overview/>) that improves medication-related decisions and patient outcomes, today announced new and expanded solutions that help address Meaningful Use Stages 1 and 2 interoperability criteria and enhance medication decision support. FDB drug knowledge experts will be demonstrating these solutions at the [HIMSS13 Conference](http://www.himssconference.org/) (<http://www.himssconference.org/>), March 3 – 7, in New Orleans, LA at the FDB booth, number 4241.

The [FDB Interoperability Module](http://www.fdbhealth.com/solutions/fdb-interoperability-module/)[™] (<http://www.fdbhealth.com/solutions/fdb-interoperability-module/>) now offers a full range of interoperable cross references between FDB clinical drug knowledge and standardized medication vocabularies designed to support the portability of patient medication, immunization, and allergy history between disparate health information systems. For instance, one recent enhancement provides RxNorm[®] mappings to FDB clinical screening content, enabling clinicians to utilize externally reported lists of RxNorm-based medication concepts in clinical screening, medication reconciliation, clinical quality measure calculations, and advanced decision support.

To guide developers in maximizing the use of FDB drug knowledge in meeting the interoperability requirements for Meaningful Use, FDB has developed a [Meaningful Use for Medications Tip Sheet](http://www.fdbhealth.com/MU2) (<http://www.fdbhealth.com/MU2>). To learn more, conference visitors are encouraged to stop by booth 4241 to meet with FDB data experts. Alternatively, the Tip Sheet is also available for download at www.fdbhealth.com/MU2

FDB will also be showcasing its latest version of [AlertSpace](http://www.fdbhealth.com/solutions/fdb-alertspace/)[®] (<http://www.fdbhealth.com/solutions/fdb-alertspace/>) which addresses the challenging industry problem of “alert fatigue” in computerized provider order entry (CPOE) and other HIT systems. FDB has released new AlertSpace functionality allowing users to customize dose checking information, including dosing ranges, frequencies, units of measure and more. The ability to customize dose checking information is in addition to current functionality including customization of drug-drug and drug-allergy detection, visibility into common customizations and collaboration features.

As part of the AlertSpace demonstration, FDB will be previewing the ONC drug-drug interaction (DDIs) subset, which will soon be incorporated into AlertSpace. This will enable users to identify a subset of high-priority alerts to activate and a set of lower-priority alerts that can be filtered.

Also featured at HIMSS13 will be the newly-released [FDB State and Federal Controlled Substances Module](http://www.fdbhealth.com/solutions/fdb-state-and-federal-controlled-substances-module/)[™] (<http://www.fdbhealth.com/solutions/fdb-state-and-federal-controlled-substances-module/>) which enables FDB customers and other industry stakeholders to easily and efficiently comply with the myriad state and federal laws aimed at reducing the fraud, waste, and abuse associated with controlled substances. This module enables efficient prescribing of controlled substances by making available the required information from state schedules directly in the electronic prescribing workflow. E-prescribing systems using this module will invoke the mandated safeguards, ensuring prescriptions are compliant with state-specific standards while reducing delays in patient care.

Visitors to the FDB booth can also preview a new module in development – the High Risk Medication Module. The initial release will encompass medications that require a Risk Evaluation and Mitigation Strategy (REMS) and medications that have a box warning. Providing this critical information to the right user at the right time, and within their normal workflow, will help to ensure regulatory compliance and improve patient safety.

About [First Databank](#) (FDB)

First Databank (FDB) provides drug knowledge that helps healthcare professionals make precise medication-related decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver a wide range of valuable, useful, and differentiated solutions. As the company that virtually launched the medication decision support category, we offer more than three decades of experience in transforming drug knowledge into actionable, targeted, and effective solutions that improve patient safety and healthcare outcomes. For a complete look at our solutions and services please visit www.fdbhealth.com or follow us on [Twitter](#) and [LinkedIn](#).